MedTrace Logo

DSUVIA Early Evaluation of Pain Trial

NCT05288348 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-04-30

Study results available
· View outcomes & findings →

Summary

Randomized, interventional trial of Emergency Department (ED) administration of DSUVIA (sufentanil) versus standard care pain management comparing pain treatment outcomes in injured patients with moderate to severe pain

Conditions

  • Traumatic Injury

Interventions

DRUG

Sufentanil 30 MCG Sublingual Tablet

30 microgram sublingual tablet administered using sublingual applicator

DRUG

standard care pain treatment

standard care pain treatment given in Emergency Department

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Frank Guyette

    lead OTHER

Principal Investigators

  • Jason Sperry, MD · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-05
Primary Completion
2024-01-21
Completion
2024-01-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05288348 on ClinicalTrials.gov